Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

(2015) Gideon M. Hirschfield et al.   GASTROENTEROLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease

(2014) Ron C. Hoogeveen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

(2014) Anand Rohatgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

(2013) Sunder Mudaliar et al.   GASTROENTEROLOGY

Antiatherogenic Functionality of High Density Lipoprotein: How Much versus How Gooden-subtitle=

(2011) Dmitri Sviridov et al.   Journal of Atherosclerosis and Thrombosis

Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte

(2010) Fan Chao et al.   ATHEROSCLEROSIS

Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation

(2009) Philippe Lefebvre et al.   PHYSIOLOGICAL REVIEWS